EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Risk of Early Recurrent Stroke and Thrombotic Events After Reperfusion Therapy in Acute Ischemic Stroke: A Meta-Analysis

Rezan Ashayeri Ahmadabad iD, Kaitlyn Sobchuk iD, Sunpreet Kaur Cheema, P N Sylaja iD, Mohammed Almekhlafi iD, Aviraj Deshmukh iD, Jesse Dawson iD, Sung-Ii Sohn iD, Laura C Gioia iD, Ashfaq Shuaib iD, Brian H Buck iD, Mahesh Kate iD

Stroke · 2026

DOI: 10.1161/strokeaha.125.050672 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Stroke, 2026. Verfasst von Rezan Ashayeri Ahmadabad und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada (R.A.A., K.S., S.K.C., A.S., B.H.B., M.K.). Hauptthemen laut MEDLINE: Ischemic Stroke, Reperfusion, Thrombolytic Therapy, Thrombosis. Die Arbeit nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Following an acute ischemic stroke, the risk of recurrent stroke is highest in the first 90 days. It is unclear whether this risk is altered by reperfusion therapy. In this meta-analysis, we aim to evaluate the risk of early recurrent stroke and other nonstroke thrombotic events postreperfusion therapy in acute ischemic stroke. METHODS: In this meta-analysis, randomized controlled trials (RCTs) were included in adults aged 18 years or older with acute ischemic stroke, comparing reperfusion treatment with best medical management (MED). We searched PUBMED, Embase, Cochrane Library, and Web of Science databases. The studies were grouped into endovascular thrombectomy (EVT) versus MED and intravenous thrombolysis versus MED. We performed a meta-analysis using a random-effects model (restricted maximum likelihood) to estimate the log risk ratio (RR) of early recurrent stroke and nonstroke thrombotic events (NSTE)—including myocardial infarction, acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and peripheral embolism—after reperfusion therapy compared with MED at 90 days after symptom onset. This study is registered with PROSPERO (The International Prospective Register of Systematic Reviews). RESULTS: A total of 15 RCTs (n=4898) comparing EVT versus MED observed no difference in early recurrent stroke (5.5%, 143/2618 versus 4.5%, 102/2280; RR, 1.2 [95% CI, 0.9–1.6]). Nine RCTs (n=7193) comparing intravenous thrombolysis versus MED observed no difference in early recurrent stroke (2%, 73/3615 versus 1.8%, 66/3578; RR, 1.1 [95% CI, 0.8–1.5]). Fourteen RCTs (n=4033) comparing EVT versus MED reported NSTE. There was no difference in NSTE in the EVT arm (3.1%, 62/2024 versus 3.1%, 62/2009; RR, 1 [95% CI, 0.7–1.4]). Five RCTs (n=4961) comparing intravenous thrombolysis versus MED observed no difference in NSTE (2%, 51/2479 versus 2.2%, 54/2482; RR, 0.9 [95% CI, 0.6–1.4]). CONCLUSIONS: Reperfusion therapies (EVT±intravenous thrombolysis) in acute ischemic stroke within 24 hours of symptom onset were not associated with increased recurrent stroke or NSTE within 90 days compared with best medical therapy. REGISTRATION URL: https://www.crd.york.ac.uk/PROSPERO/ ; Unique identifier: CRD42024542020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ischemic StrokeReperfusionThrombolytic TherapyThrombosisHumansRecurrenceThrombectomyRandomized Controlled Trials as TopicEndovascular Procedures

Stichwörter der Autor:innen

ischemic strokerecurrenceriskthrombectomythrombosistissue-type plasminogen activator

Autor:innen und Institutionen

  • Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada (R.A.A., K.S., S.K.C., A.S., B.H.B., M.K.).
  • Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India (P.N.S.).
  • Department of Clinical Neurosciences, University of Calgary, AB, Canada (M.A.).
  • Division of Clinical Science, Health Sciences North, Northern Ontario School of Medicine, Sudbury, Canada (A.D.).
  • School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom (J.D.).
  • Department of Neurology, Keimyung University Dongsan Medical Center, Daegu, South Korea (S.-I.S.).

ORCID-Profile: Rezan Ashayeri Ahmadabad, Kaitlyn Sobchuk, P N Sylaja, Mohammed Almekhlafi, Aviraj Deshmukh, Jesse Dawson, Sung-Ii Sohn, Laura C Gioia, Ashfaq Shuaib, Brian H Buck, Mahesh Kate

Zitieren

APA

Ashayeri Ahmadabad, R., Sobchuk, K., Cheema, S. K., Sylaja, P. N., Almekhlafi, M., Deshmukh, A., Dawson, J., Sohn, S. I., Gioia, L. C., Shuaib, A., Buck, B. H., & Kate, M. (2026). Risk of Early Recurrent Stroke and Thrombotic Events After Reperfusion Therapy in Acute Ischemic Stroke: A Meta-Analysis. Stroke. https://doi.org/10.1161/strokeaha.125.050672

Vancouver

Ashayeri Ahmadabad R, Sobchuk K, Cheema SK, Sylaja PN, Almekhlafi M, Deshmukh A, et al. Risk of Early Recurrent Stroke and Thrombotic Events After Reperfusion Therapy in Acute Ischemic Stroke: A Meta-Analysis. Stroke. 2026. doi:10.1161/strokeaha.125.050672

BibTeX
@article{AshayeriAhmadabad2026,
  author = {Ashayeri Ahmadabad, Rezan and Sobchuk, Kaitlyn and Cheema, Sunpreet Kaur and Sylaja, P N and Almekhlafi, Mohammed and Deshmukh, Aviraj and Dawson, Jesse and Sohn, Sung-Ii and Gioia, Laura C and Shuaib, Ashfaq and Buck, Brian H and Kate, Mahesh},
  title = {Risk of Early Recurrent Stroke and Thrombotic Events After Reperfusion Therapy in Acute Ischemic Stroke: A Meta-Analysis},
  journal = {Stroke},
  year = {2026},
  doi = {10.1161/strokeaha.125.050672}
}
Kostenlos starten →